2. Immunology/Inflammation Apoptosis Cytoskeleton
  3. Interleukin Related Apoptosis Caspase Cadherin
  4. Tralokinumab

Tralokinumab  (Synonyms: CAT354)

Cat. No.: HY-P99053 Purity: 99.12%
SDS
COA
Technical Support

Tralokinumab (CAT354) is a humanized IgG4 monoclonal antibody that specifically binds to and neutralizes IL-13. Tralokinumab can be used in the research of diseases such as asthma, atopic dermatitis, and pulmonary fibrosis.

For research use only. We do not sell to patients.

CAS No. : 1044515-88-9

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Tralokinumab Featured Recommendations:

Tralokinumab Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Tralokinumab

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22

View All Caspase Isoform Specific Products:

View All Isoforms
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Tralokinumab (CAT354) is a humanized IgG4 monoclonal antibody that specifically binds to and neutralizes IL-13. Tralokinumab can be used in the research of diseases such as asthma, atopic dermatitis, and pulmonary fibrosis[1][2].

IC50 & Target[1]

IL-13

 

In Vivo

Tralokinumab (3 mg/kg; intraperitoneal injection; once every other day; from day 35 to day 63) can inhibit pulmonary fibrosis and reduce epithelial cell apoptosis in a humanized SCID mouse model of pulmonary fibrosis[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female C.B-17-scid-beige (C.B-17SCID/bg) mice received single-cell preparations of IPF and normal fibroblasts via tail vein injection[2]
Dosage: 3 mg/kg
Administration: Intraperitoneal injection; once every other day; from day 35 to day 63
Result: Blocked aberrant lung remodeling, promoted lung repair and restored epithelial integrity.
Significantly decreased fibrotic alterations.
Reduced serum CC16 (a marker of epithelial injury) and reduced BAL caspase 3 activity.
Enhanced the expression of epithelial-associated genes, including E-cadherin and all of the surfactants.
Clinical Trial
Molecular Weight

144140.00

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Tralokinumab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG4 lambda
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Tralokinumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Tralokinumab1044515-88-9CAT354CAT 354CAT-354Interleukin RelatedApoptosisCaspaseCadherinILIgG4 monoclonal antibodyIL-13atopic dermatitispulmonary fibrosis modelInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Tralokinumab
Cat. No.:
HY-P99053
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.